This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Etten, B. Articles by Eggermont, A. M. M. Search for Related Content PubMed PubMed Citation Articles by van Etten, B. Articles by Eggermont, A. M. M. Related Collections Surgery

Fifty Tumor Necrosis Factor–Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors

From the Department of Surgical Oncology, University Hospital Rotterdam-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

Correspondence: Address correspondence and reprint requests to: Alexander M. M. Eggermont, MD, PhD, Department of Surgical Oncology, University Hospital Rotterdam-Daniel den Hoed Cancer Center, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands; Fax: 31-10-439-1011; E-mail: eggermont{at}chih.azr.nl

Background: Isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan is highly effective in treating limb-threatening soft tissue sarcoma (STS) and other bulky tumors. Because of fear of TNF-associated toxicity, ILP with TNF is not offered to older patients in some cancer centers, although especially in older patients, every attempt to avoid an amputation that may end their independence must be considered.

Methods: Out of 306 TNF-based ILPs, 50 ILPs were performed for limb salvage in 43 patients >75 years old (range, 75–91 years): 29 STS and 14 melanoma patients.

Results: In the STS patients, a response rate of 76% and a limb-salvage rate of 76% were achieved; in the melanoma patients, a 100% response rate and a 93% limb-salvage rate were achieved. Local toxicity was mild. The three postoperative deaths that occurred in the total series of 306 TNF-based ILPs in Rotterdam (<1%) occurred in patients >75 years old after leakage-free perfusions and were not related to TNF but to extremely high-risk profiles in these three patients.

Conclusions: Older patients should not be withheld a TNF-based ILP for limb salvage, because the procedure is safe and highly effective in these patients.

This article has been cited by other articles:

				M. L. Hoven-Gondrie, K. M. J. Thijssens, J. H. B. Geertzen, E. Pras, R. J. van Ginkel, and H. J. Hoekstra Isolated Limb Perfusion and External Beam Radiotherapy for Soft Tissue Sarcomas of the Extremity: Long-Term Effects on Normal Tissue According to the LENT-SOMA Scoring System Ann. Surg. Oncol., May 1, 2008; 15(5): 1502 - 1510. [Abstract] [Full Text] [PDF]

				R. van Horssen, T. L. M. ten Hagen, and A. M. M. Eggermont TNF-{alpha} in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. Oncologist, April 1, 2006; 11(4): 397 - 408. [Abstract] [Full Text] [PDF]

				D. J. Grunhagen, B. van Etten, F. Brunstein, W. J. Graveland, A. N. van Geel, J. H. W. de Wilt, and A. M. M. Eggermont Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor {alpha} and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure Ann. Surg. Oncol., August 1, 2005; 12(8): 609 - 615. [Abstract] [Full Text] [PDF]

				N. Lassau, M. Lamuraglia, D. Vanel, A. Le Cesne, L. Chami, S. Jaziri, P. Terrier, A. Roche, J. Leclere, and S. Bonvalot Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases Ann. Onc., July 1, 2005; 16(7): 1054 - 1060. [Abstract] [Full Text] [PDF]

				E. M. Noorda, B. C. Vrouenraets, O. E. Nieweg, F. van Coevorden, and B. B.R. Kroon Isolated Limb Perfusion: What Is the Evidence for Its Use? Ann. Surg. Oncol., September 1, 2004; 11(9): 837 - 845. [Abstract] [Full Text] [PDF]